MGX
NASDAQ · Biotechnology
Metagenomi Therapeutics Inc
$1.54
+0.13 (+9.22%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 23.21M | 24.43M | 24.83M |
| Net Income | -6,058,807 | -7,358,364 | -5,671,741 |
| EPS | — | — | — |
| Profit Margin | -26.1% | -30.1% | -22.8% |
| Rev Growth | +13.9% | -4.6% | +12.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 7.88M | 7.97M | 8.62M |
| Total Equity | 20.88M | 19.49M | 21.00M |
| D/E Ratio | 0.38 | 0.41 | 0.41 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -8,420,768 | -8,749,975 | -9,471,019 |
| Free Cash Flow | -5,731,518 | -5,557,893 | -4,395,902 |